Updates

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART III

Dec 28, 2021

Part III: Big Pharma Maintains Price-Hiking, Patent-Gaming Business-As-Usual Read More

DOSE OF REALITY: OVERSIGHT REPORT EXPOSES BIG PHARMA’S EGREGIOUS PRICING & ANTI-COMPETITIVE TACTICS — DEBUNKS INNOVATION RHETORIC

Dec 12, 2021

Investigation Finds Big Pharma Hiked Prices More Than 250 Times On Just 12 Top Read More

CSRXP: LANDMARK OVERSIGHT REPORT DEBUNKS BIG PHARMA’S FALSE RHETORIC, ADDS TO MOMENTUM TO LOWER RX PRICES

Dec 10, 2021

U.S. House Oversight & Reform Committee Report Finds Big Pharma’s Read More

SECOND OPINION: BIG PHARMA DOUBLES DOWN ON BLAME GAME STRATEGY AMID UNPRECEDENTED MOMENTUM TO LOWER RX PRICES

Dec 3, 2021

New PhRMA Ad Campaign Aims to Dodge Accountability, Push Pharma-Backed Rebate Read More

BIG PHARMA WATCH: UNJUSTIFIED PRICE HIKES ON JUST SEVEN BRAND NAME DRUGS COST U.S. $1.6 BILLION IN 2020

Nov 16, 2021

New Analysis Underscores How Big Pharma’s Price Increases Cost The American Read More

BIG PHARMA EARNINGS WATCH: ASTRAZENECA

Nov 15, 2021

AstraZeneca’s Q3 Earnings Report Shows Pandemic Price Hikes Profitable for Read More

CSRXP: BIG PHARMA’S EGREGIOUS PRICING OF UNPROVEN ALZHEIMER’S TREATMENT DRIVES HIGHER PREMIUMS FOR SENIORS

Nov 12, 2021

Biogen’s Staggering $56,000 Price Tag for Treatment With No Proven Clinical Read More

BIG PHARMA EARNINGS WATCH: SANOFI, ABBVIE, PFIZER & AMGEN

Nov 9, 2021

New Round of Q3 Earnings Reports Continue to Show Big Pharma Profits Buoyed By Read More

BIG PHARMA WATCH: BIG PHARMA SPENDS $263M ON LOBBYING, CAMPAIGN DONATIONS FIGHTING SOLUTIONS TO LOWER RX PRICES

Nov 4, 2021

New Analysis Highlights How Big Pharma Uses Limitless Resources Read More

CSRXP APPLAUDS INCLUSION OF PRESCRIPTION DRUG PRICING SOLUTIONS IN LATEST FRAMEWORK

Nov 2, 2021

Congress Should Reject Pharma-backed Proposals That Would Hike Health Care Read More

BIG PHARMA EARNINGS WATCH: NOVARTIS, MERCK, GLAXO SMITH KLINE, BRISTOL-MYERS SQUIBB

Nov 1, 2021

New Q3 Earnings Reports Underscore How Price Hikes, Anti-Competitive Tactics Read More